L-glutathione

Meta-analysis of seven randomized controlled trials involving 450 participants with Parkinson's disease receiving glutathione treatment. Pooled analysis showed glutathione significantly improved Unified Parkinson's Disease Rating Scale (UPDRS) scores including UPDRS I (activities of daily living), UPDRS II (motor examination), and UPDRS III subscores compared to controls. Subgroup analysis by dosage (300mg vs 600mg) demonstrated dose-dependent effects. Study concludes glutathione shows efficacy and safety for PD treatment with improvements in disability scores, though larger trials with longer follow-up needed to establish optimal dosing protocols.

Comprehensive review tracing discoveries leading to understanding of glutathione peroxidases from Mills' 1957 identification of cytosolic GPx through Rotruck's 1972 selenium dependence determination establishing GPx1 as first vertebrate selenoenzyme. Details enzymatic mechanism involving selenocysteine catalytic component enabling rapid H₂O₂ reaction and GSH reduction. Discusses family expansion to multiple isozymes preventing free radical formation from hydroperoxides across cellular compartments. GPx1 knockout mice studies demonstrate irreplaceable role in protecting against systemic acute oxidative stress despite compensatory mechanisms under normal conditions.

This comprehensive review examines the therapeutic potential of NAD+ precursors in combating age-related diseases. The study found that NAD+ decreases with age in certain tissues, and age-related NAD+ depletion affects numerous biological processes crucial for maintaining cellular homeostasis. The research provides a thorough analysis of how NAD+ supplementation can address age-related decline.

Key Findings:

Age-Related Decline: Documented NAD+ depletion in aging tissues

Cellular Homeostasis: Critical role in maintaining cellular function

Therapeutic Applications: Multiple age-related conditions may benefit from NAD+ precursors

Mechanism of Action: Detailed explanation of how supplementation works at cellular level

Reviews nucleophilic conjugation of GSH with electrophilic compounds as detoxification system comprising GSH, glutathione S-transferases, and GS-X export pumps. Thiolate anion (GS⁻) acts as soft nucleophile sensing reactivity of soft electrophiles. Phase II conjugation forms water-soluble GSH S-conjugates transported out of cells, with Phase III metabolism involving gamma-glutamyl transferase cleavage and cysteinylglycine dipeptidase processing. Some conjugates undergo bioactivation via cysteine S-conjugate beta-lyases producing toxic metabolites. System critical for anticancer drug metabolism affecting therapeutic efficacy and resistance development.

Randomized placebo-controlled double-blind trial in 21 PD patients with inadequately controlled motor symptoms assigned to IV glutathione 1400mg or placebo three times weekly for 4 weeks. Glutathione well tolerated with no withdrawals due to adverse events. Reported adverse events similar between groups. Results showed preliminary evidence of safety and tolerability though efficacy endpoints not significantly different from placebo in this small pilot study. Study establishes feasibility of larger trials to definitively assess therapeutic benefit of IV glutathione administration in Parkinson's disease.

Proton magnetic resonance spectroscopy study in 15 mid-stage PD participants evaluating whether intranasal GSH (200mg) augments CNS glutathione concentrations. Serial measurements over 1 hour post-administration showed overall brain GSH increase relative to baseline (P<0.001). No increase at 8 minutes but significantly elevated at all subsequent timepoints (P<0.01). Study demonstrates intranasal GSH crosses blood-brain barrier and increases brain glutathione levels, supporting ongoing trials optimizing dosing and assessing therapeutic efficacy. Addresses critical question of whether administered glutathione reaches target CNS tissue in neurodegenerative disease.

12-week randomized double-blind placebo-controlled trial in 124 Asian females comparing L-Cystine 500mg + L-Glutathione 250mg combination versus individual components and placebo. Combination therapy showed superior skin lightening and anti-dark spot effects measured by melanin index reduction and colorimetry. Mechanism involves glutathione's anti-melanogenic properties skewing melanin synthesis toward lighter pheomelanin instead of darker eumelanin. Results support synergistic benefits of cysteine-glutathione combination for depigmentation compared to monotherapy, with good safety profile and no significant adverse events reported.

Animal study in female BALB/c mice receiving 100mg/kg oral L-glutathione with UVB irradiation (250 mJ/cm² for 3 minutes on days 9, 11, 13 of 14-day treatment). L-glutathione significantly reduced lipid peroxidation, elevated superoxide dismutase activity and glutathione levels (P<0.05). Melanin content and tyrosinase activity significantly inhibited versus UVB-irradiated controls (P<0.05). Histopathological analysis confirmed reduced melanin deposition. Mechanism involves direct tyrosinase inactivation via copper-binding active site interaction. Results demonstrate photoprotective properties through dual action on oxidative stress prevention and melanogenesis downregulation.

In vitro mechanistic study examining glutathione effects on tyrosinase-L-DOPA melanin synthesis reaction. Glutathione dose-dependently inhibited melanin synthesis with inhibition reversed by increasing L-DOPA concentration but not tyrosinase concentration. Glutathione inhibited binding between tyrosinase and L-DOPA substrate. Synthesized melanin normally aggregates within 1 hour but aggregation prevented by glutathione addition. Results indicate glutathione inhibits both synthesis and agglutination of melanin by interrupting L-DOPA function, providing molecular basis for skin-lightening applications through substrate interference mechanism rather than direct enzyme inhibition.

Randomized double-blind placebo-controlled trial in 60 participants receiving oral glutathione 500mg daily for 4 weeks. Melanin indices decreased consistently at all six body sites in glutathione group with statistically significant reductions versus placebo at right face and sun-exposed left forearm (p=0.021 and p=0.036 respectively). UV spot changes measured by VISIA imaging similarly reflected improvements. Both glutathione and placebo very well tolerated with no significant adverse events. Study provides preliminary evidence for oral glutathione skin-lightening effects though long-term safety not established, warranting larger extended clinical trials.

Comprehensive review of GPx-1 as intracellular antioxidant enzyme enzymatically reducing hydrogen peroxide to water. GPx-1 knockout studies show enhanced susceptibility to H₂O₂-induced apoptosis correlating with increased ROS accumulation and decreased PI3K/Akt survival pathway activation. Cells from GPx-1-/- mice including neurons, SMCs, astrocytes, fibroblasts, and EPCs exhibit enhanced peroxide-mediated cell death. Overexpression studies show GPx-1 protects against oxidant-induced mitochondrial DNA damage and enhances resistance to chemotherapy drugs like doxorubicin. GPx-1 modulates hydrogen peroxide-dependent signal transduction and maintains thiol redox balance beyond direct antioxidant functions.